Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …

Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …

Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …

In order to address the world-wide health challenge caused by the COVID-19 pandemic, the
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …

Coronaviruses (CoVs) have continuously posed a threat to human and animal health.
However, existing antiviral drugs are still insufficient in overcoming the challenges caused …

Influenza A virus (IAV) is a common respiratory pathogen and a global cause of significant
and often severe morbidity. Although inflammatory immune responses to IAV infections are …

Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at
the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has …

Currently, the clinically approved repertoire of antiviral drugs predominantly comprises direct-
acting antivirals (DAAs). However, the use of DAAs is frequently limited by adverse effects …

Inhibitors of the SARS-CoV-2 main protease (Mpro) such as nirmatrelvir (NTV) and
ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the …

COVID-19 pandemic is predominantly caused by SARS-CoV-2, with its main protease,
Mpro, playing a pivotal role in viral replication and serving as a potential target for inhibiting …